Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk A/S
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
To compare the effect of once-weekly dosing of two dose levels of subcutaneous semaglutide (0.5 mg and 1.0 mg) versus once-weekly dosing of two dose levels of subcutaneous dulaglutide (0.75 mg and 1.5...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Paediatric Subjects with Congenital Factor XIII A-subunit Deficiency Safety Extension Trial to F13CD-3760
To evaluate the long term safety of monthly replacement therapy with rFXIII when used for prevention of bleeding episodes in paediatric subjects with congenital FXIII A-subunit deficiency
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus Wirksamkeit und Sicherheit von oral verabreichtem Semaglutid bei flexibler Dosisanpassung aufgrund klinischer Beurteilung im Vergleich zu Sitagliptin bei TeilnehmerInnen mit Typ-2-Diabetes mellitus
To compare the effect of once-daily dosing of oral semaglutide using a flexible dose adjustment based on clinical evaluation versus sitagliptin once-daily, both in combination with 1-2 oral antidiabet...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083) in Growth Hormone deficient adults (AGHD)
To determine safety and tolerability of ascending multiple subcutaneous (sc) doses of NNC126-0083 in AGHD male and female subjects compared to placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial investigating the pharmacokinetic properties of FIAsp in children, adolescents and adults with type 1 diabetes
To compare the total exposure of FIAsp between children, adolescents and adult subjects with type 1 diabetes.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, open-labelled, single dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083) compared to Norditropin NordiFlex in growth hormone deficient children
To determine safety and tolerability of single subcutaneous (sc) doses of pegylated long-acting human growth hormone (NNC126-0083) compared to 7 days treatment with sc doses of Norditropin NordiFlex® ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A Trial Investigating the Pharmacokinetic Properties of NN5401 in Children, Adolescents and Adults with Type 1 Diabetes
To investigate the total exposure of SIAC in children, adolescents and adult subjects with type 1 diabetes
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A Trial to Test for Bioequivalence between Two NN1250 Formulations in Healthy Subjects
The primary objective is to test for bioequivalence between two formulations of SIBA (IDeg) based on AUCI454,0-120h,SD and Cmax,I454,SD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension period
•To assess and compare the effect on glycaemic control (as measured by HbA1c) of once daily administration of three doses of liraglutide in combination with metformin versus metformin monotherapy vers...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in paediatric previously untreated patients with Haemophilia A
To evaluate safety of turoctocog alfa in paediatric previously untreated patients (PUP) with haemophilia A
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant